All Dan Grossman articles
-
News
Galapagos set for small molecule and biologics pivot after cell therapy exit
But the Belgium biotech’s decision to winddown the cell business will cause it to cut around 90 percent of its headcount.
But the Belgium biotech’s decision to winddown the cell business will cause it to cut around 90 percent of its headcount.